Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
Nogin announces compliance with Nasdaq listing rule regarding form 10-Q filing
Post Content Post Views: 79
Pacer American Energy Independence ETF declares monthly distribution of $0.1200
Post Content Post Views: 99
Li Auto and XPeng look to break into potentially lucrative MPV segment in China
Post Content Post Views: 86
Taiwanese Tesla supplier Hota retools supply chain with first US factory
Post Content Post Views: 95
Blockchain devs expect complications from EU smart contract kill switch
Post Content Post Views: 89
SuperBuzz announces private placement
Post Content Post Views: 98